Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Accumulated Expenses (2018 - 2025)

Tg Therapeutics has reported Other Accumulated Expenses over the past 8 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $2.1 million for Q4 2025, down 54.1% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (down 54.1% YoY), and the annual figure for FY2025 was $2.1 million, down 54.1%.
  • Other Accumulated Expenses for Q4 2025 was $2.1 million at Tg Therapeutics, up from $2.0 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for TGTX hit a ceiling of $14.5 million in Q1 2021 and a floor of $807000.0 in Q3 2022.
  • Median Other Accumulated Expenses over the past 5 years was $2.1 million (2025), compared with a mean of $4.0 million.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 93.61% in 2022 and later skyrocketed 232.84% in 2024.
  • Tg Therapeutics' Other Accumulated Expenses stood at $1.5 million in 2021, then dropped by 22.69% to $1.2 million in 2022, then grew by 26.52% to $1.5 million in 2023, then surged by 212.85% to $4.6 million in 2024, then crashed by 54.1% to $2.1 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $2.1 million (Q4 2025), $2.0 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.